Wolf Greenfield Promotes Three Attorneys to Shareholder

By Press Releases
January 8, 2016

Intellectual property law firm Wolf, Greenfield & Sacks, P.C. recently announced the promotion of Y. Jenny Chen, Thomas A. Franklin and Jessamine N. Lee to the position of shareholder, effective January 1, 2016. The promoted attorneys represent a range of practice areas, including biotechnology, chemical and materials technologies and electrical and computer technologies.

“Wolf Greenfield’s reputation is built on the industry-leading expertise and dedication that our attorneys deliver to our clients every day,” said Tim Oyer, Wolf Greenfield’s president and managing partner. “We are proud to retain the best legal talent, and Jenny, Tommy and Jas each reflect the firm’s commitment to excellence. It’s an honor to work alongside them and to recognize their outstanding work by promoting each to shareholder.”

jenny-chenJenny Chen focuses her practice on U.S. and foreign patent prosecution and portfolio strategy, opinion work, due diligence, and post-grant matters such as interference, inter partes review and reexamination. Jenny counsels clients in the areas of biological, medical and pharmaceutical sciences. She has worked on projects related to biosimilars, diagnosis and treatment for various diseases, vaccine technologies, drug discovery, antibiotic biosynthesis, medical implants, gene- and cell-based therapies, pharmaceutical formulations and herb extracts.

thomas-franklinThomas Franklin provides a wide range of IP services including strategic patent portfolio development, conducting and defending due diligence, development of licensing agreements, patent validity and infringement opinions and litigation-related counseling for both plaintiffs and defendants. Drawing on his broad technical background, he works with clients spanning numerous technical fields, including medical devices, electromagnetic sensors, optics, microelectromechanical systems (MEMS), semiconductors and fluidic systems.

jessamine-leeJessamine (Jas) Lee works with clients in IP strategy development and execution, including IP portfolio management, U.S. and foreign patent prosecution, non-infringement and invalidity opinions, and due diligence. She counsels a variety of clients including start-up companies, large global corporations, venture capital firms and academic institutions on U.S. and international patent issues. Jas has a broad technical background including expertise in the areas of microfluidics, medical devices and diagnostics, drug delivery, bioreactors, cleantech technologies, electrochemical devices, nanotechnology, microfabrication, materials chemistry, organic chemistry and pharmaceuticals.

About Wolf Greenfield

Wolf, Greenfield & Sacks, P.C. is the largest Boston-based law firm focused solely on intellectual property (IP) law. The firm’s lawyers are technical and legal specialists at the forefront of their fields supporting leading companies, inventors, and research facilities with a full range of intellectual property portfolio management including patent, copyright and trademark acquisition, prosecution and litigation; opinions and strategic counseling; trade dress protection; intellectual property audits and due diligence; and licensing and other issues related to commercialization of intellectual property. Now in its ninth decade, Wolf Greenfield continues to represent innovators in the fields of biotechnology, chemical & materials technologies, pharmaceuticals, clean technology, electrical & computer technologies, mechanical technologies, medical devices, and consumer products.


EDITORIAL NOTE: If you have news relating to hiring or promotion of intellectual property attorneys please send us the press release

The Author

Press Releases

Press Releases : Industry news brought to you by IPWatchdog.com

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

There are currently No Comments comments.